PL2723336T3 - Kompozycje do leczenia zespołu łamliwego chromosomu X - Google Patents
Kompozycje do leczenia zespołu łamliwego chromosomu XInfo
- Publication number
- PL2723336T3 PL2723336T3 PL12735048T PL12735048T PL2723336T3 PL 2723336 T3 PL2723336 T3 PL 2723336T3 PL 12735048 T PL12735048 T PL 12735048T PL 12735048 T PL12735048 T PL 12735048T PL 2723336 T3 PL2723336 T3 PL 2723336T3
- Authority
- PL
- Poland
- Prior art keywords
- fragile
- syndrome
- compositions
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11171532A EP2540295A1 (en) | 2011-06-27 | 2011-06-27 | Compositions for the treatment of Fragile X syndrome |
| EP12735048.6A EP2723336B1 (en) | 2011-06-27 | 2012-06-19 | Compositions for the treatment of fragile x syndrome |
| PCT/IB2012/053089 WO2013001412A1 (en) | 2011-06-27 | 2012-06-19 | Compositions for the treatment of fragile x syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2723336T3 true PL2723336T3 (pl) | 2020-10-19 |
Family
ID=44840530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12735048T PL2723336T3 (pl) | 2011-06-27 | 2012-06-19 | Kompozycje do leczenia zespołu łamliwego chromosomu X |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10435366B2 (pl) |
| EP (2) | EP2540295A1 (pl) |
| JP (1) | JP6012726B2 (pl) |
| DK (1) | DK2723336T3 (pl) |
| ES (1) | ES2797395T3 (pl) |
| PL (1) | PL2723336T3 (pl) |
| PT (1) | PT2723336T (pl) |
| WO (1) | WO2013001412A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2540295A1 (en) * | 2011-06-27 | 2013-01-02 | Centre national de la recherche scientifique | Compositions for the treatment of Fragile X syndrome |
| AU2014233048B2 (en) * | 2013-03-15 | 2019-01-03 | The Children's Hospital Of Philadelphia | Magnetoencephalography biomarkers of GABA-B agonist drug activity in autism spectrum disorders |
| EP3256112A1 (en) | 2015-02-13 | 2017-12-20 | Canbex Therapeutics Limited | Compounds for treating disorders associated with bk channel modulation |
| WO2018157046A1 (en) | 2017-02-24 | 2018-08-30 | Ovid Therapeutics Inc. | Methods of treating seizure disorders |
| EP3727587A4 (en) * | 2017-12-22 | 2022-02-23 | Massachusetts Institute Of Technology | COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS) |
| EP3912625A1 (en) | 2020-05-20 | 2021-11-24 | Kaerus Bioscience Limited | Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565483A (en) | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
| CA2425771A1 (en) * | 2000-10-13 | 2002-04-18 | Christopher G. Boissard | Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| WO2002066426A2 (en) * | 2001-02-20 | 2002-08-29 | Bristol-Myers Squibb Company | Fluoro oxindole derivatives as modulators of kcnq potassium channels |
| CA2438868A1 (en) * | 2001-02-20 | 2002-09-19 | Valentin K. Gribkoff | Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases |
| FR2857452B1 (fr) * | 2003-07-11 | 2005-09-30 | Univ Rabelais Francois | Test de depistage de l'autisme, methode de selection de patients repondant audit test et utilisation des medicaments activateurs de canaux bkca pour le traitement de ladite maladie |
| DE102004053673A1 (de) * | 2004-11-03 | 2006-05-04 | Endress + Hauser Flowtec Ag | Vorrichtung zur Bestimmung und/oder Überwachung des Volumen- und/oder Massendurchflusses eines Mediums |
| EP2433635A1 (en) | 2006-11-10 | 2012-03-28 | Massachusetts Institute Of Technology | PAK Modulators |
| EP2175886A1 (en) * | 2007-06-28 | 2010-04-21 | CNSBio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
| EP2540295A1 (en) * | 2011-06-27 | 2013-01-02 | Centre national de la recherche scientifique | Compositions for the treatment of Fragile X syndrome |
-
2011
- 2011-06-27 EP EP11171532A patent/EP2540295A1/en not_active Withdrawn
-
2012
- 2012-06-19 WO PCT/IB2012/053089 patent/WO2013001412A1/en active Application Filing
- 2012-06-19 ES ES12735048T patent/ES2797395T3/es active Active
- 2012-06-19 DK DK12735048.6T patent/DK2723336T3/da active
- 2012-06-19 US US14/128,154 patent/US10435366B2/en active Active
- 2012-06-19 PL PL12735048T patent/PL2723336T3/pl unknown
- 2012-06-19 JP JP2014518000A patent/JP6012726B2/ja active Active
- 2012-06-19 EP EP12735048.6A patent/EP2723336B1/en active Active
- 2012-06-19 PT PT127350486T patent/PT2723336T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014518255A (ja) | 2014-07-28 |
| JP6012726B2 (ja) | 2016-10-25 |
| US20140221450A1 (en) | 2014-08-07 |
| ES2797395T3 (es) | 2020-12-02 |
| EP2723336A1 (en) | 2014-04-30 |
| EP2723336B1 (en) | 2020-04-08 |
| DK2723336T3 (da) | 2020-06-29 |
| WO2013001412A1 (en) | 2013-01-03 |
| PT2723336T (pt) | 2020-07-14 |
| EP2540295A1 (en) | 2013-01-02 |
| US10435366B2 (en) | 2019-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191948T1 (hr) | Postupci za liječenje alportovog sindroma | |
| IL232154A0 (en) | pak inhibitors for the treatment of fragile x syndrome | |
| HK1197400A1 (zh) | 治療 的化合物 | |
| ZA201309262B (en) | Absorbent structure for absorbent articles | |
| HK1198012A1 (zh) | 用於治療瘻的組合物 | |
| PL2717820T3 (pl) | Struktura chłonna do wyrobów chłonnych | |
| EP2683792A4 (en) | NEW ETCHING COMPOSITION | |
| SG11201400939YA (en) | Process for the preparation of methoxymelonal | |
| PL2723336T3 (pl) | Kompozycje do leczenia zespołu łamliwego chromosomu X | |
| PT2651251T (pt) | Composição para o tratamento de distúrbios metabólicos | |
| EP2624841A4 (en) | COMPOSITIONS FOR TREATING CHRONIC VIRAL INFECTIONS | |
| IL231498B (en) | Preparations for the treatment of peripheral ulcers of various sources | |
| ZA201308776B (en) | Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome | |
| PL2674409T3 (pl) | Kompozycja ceramiczna | |
| PL2841079T3 (pl) | Nowe kompozycje do leczenia przewlekłych owrzodzeń | |
| HUP1100268A2 (en) | Nasale composition for the prevention of venous trombosis | |
| AU2011900519A0 (en) | Drug compositions for the treatment of insomnia | |
| PL394420A1 (pl) | Sposób wytwarzania dilauroilofluoresceiny | |
| PL394378A1 (pl) | Sposób otrzymywania E-2-amino-4-nitrostilbenów |